SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
XPD Lys751Gln polymorphism is not associated with oral cancer risk: evidence from a meta-analysis.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.
- Association of ERCC2/XPD polymorphisms and the risk of head and neck carcinoma: a systematic review, meta-analysis, trial sequential analysis, network analysis, and functional effects.BMC oral health · 2025Pooled it
- The association between XPD rs13181 and rs1799793 polymorphism and oral cancer risk: evidence from a meta-analysis.BMC cancer · 2024Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several studies have investigated the association between xeroderma pigmentosum group D (XPD) Lys751Gln polymorphism and oral cancer. However, the impact of XPD Lys751Gln polymorphism on oral cancer risk is unclear, owing to the obvious inconsistence among those studies. The aim of this study was to derive a more precise estimation of the association of XPD Lys751Gln polymorphism with oral cancer by performing a meta-analysis. Data were analyzed using Stata, and publication bias was estimated. We included seven study populations, comprising 1,093 cases and 2,637controls from seven publications. The pooled odds ratio (OR) with their 95 % confidence interval (95 % CI) was calculated to assess the association between XPD Lys751Gln polymorphism and risk of oral cancer. Overall, there was no association between XPD Lys751Gln polymorphism and oral cancer risk under all genetic models (Gln/Gln versus Lys/Lys: OR = 1.23, 95 % CI 0.78-1.96, p = 0.04; Lys/Gln + Gln/Gln versus Lys/Lys: OR = 1.13, 95 % CI 0.87-1.48, p = 0.03; Gln/Gln versus Lys/Gln + Lys/Lys: OR = 1.14, 95 % CI 0.79-1.63, p = 0.16; Lys/Gln versus Lys/Lys: OR = 1.12, 95 % CI 0.89-1.40, p = 0.131). Subgroup analysis by ethnicity suggested that there was no association between XPD Lys751Gln polymorphism and oral cancer risk in both Asians and Caucasians. These results suggest that XPD Lys751Gln polymorphism is not related to oral cancer risk. Further large and well-designed studies are required to confirm this conclusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.